Stock Financial Ratios

CERC / Cerecor Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)11.28
Enterprise Value ($M)4.36
Book Value ($M)0.21
Book Value / Share0.02
Price / Book4.57
NCAV ($M)0.10
NCAV / Share0.16
Price / NCAV4.79
Income Statement (mra) ($M)
Net Income-16.47
Balance Sheet (mrq) ($M)
Cash & Equivalents24.00
Cash / Share2.23
Quick Ratio1.31
Current Ratio1.31
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-6.43
Return on Assets (ROA)-2.86
Return on Equity (ROE)-79.57
Identifiers and Descriptors
Central Index Key (CIK)1534120
Industry Groups
SIC 2834 - Pharmaceutical Preparations
Share Statistics
Preferred Stock Shares Outstanding0
Common Shares Outstanding10,744,959
Common Stock Shares Outstanding9,434,141
Scoring Models
Piotroski F-Score0.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Kaplan-Zingales KZ-IndexN/A
Cash Conversion CycleN/A
Per Share Metrics
Cash And Equivalents Per Share2.23
Minority Interest Per Share0.00
Current Portion Of Long Term Debt Per Share0.00
Property Plant And Equipment Gross Per Share0.00
Accounts Receivable Per Share0.00
Property Plant And Equipment Per Share0.00
Inventory Raw Materials Per Share0.00
Long Term Debt Per Share0.00
Treasury Stock Per Share0.00
Assets Other Current Per Share0.00
Accounts Payable Per Share0.00
Preferred Stock Value Outstanding Per Share0.00
Assets Non Current Per Share0.00
Inventory Per Share0.00
Retained Earnings Per Share0.00
Liabilities And Stock Equity Per Share0.00
Assets Other Non Current Per Share0.00
Cash Per Share2.23
Inventory Work In Progress Per Share0.00
Assets Current Per Share2.62
Property Plant And Equipment Net Per Share0.00
Additional Paid In Capital Per Share0.00
Liabilities Current Per Share0.00
Debt Per Share0.00
Assets Per Share0.00
Deferred Income Tax Liabilities Per Share0.00
Inventory Finished Goods Per Share0.00
Liabilities Per Share0.57
Liabilities Other Non Current Per Share0.00
Intangibles Per Share0.00
Goodwill Per Share0.00
Accumulated Depreciation And Depletion Per Share0.00
Equity Per Share0.00

Peers - Pharmaceutical Preparations (2834)

CERC : Cerecor Stock Analysis and Research Report

Cerecor is a biopharmaceutical company that is developing innovative drug candidates to make a difference in the lives of patients with neurologic and psychiatric disorders. The company's lead drug candidate is CERC-301, which the company currently intend to explore as a novel treatment for orphan neurologic indications. The company also have two pre-clinical stage compounds, CERC-611 and CERC-406.

The company's portfolio of product candidates is summarized below:

  • CERC-301: Orphan Neurologic Diseases. CERC‑301 belongs to a class of compounds known as antagonists of the N‑methyl‑D‑aspartate, or NMDA, receptor, a receptor subtype of the glutamate neurotransmitter system that is responsible for controlling neurologic adaptation. The company believe CERC‑301 specifically blocks the NMDA receptor subunit 2B, or NR2B. Cerecor has conducted two Phase 2 studies with this drug candidate as a potential adjunctive treatment for major depressive disorders, or MDD, in which the company obs...
Click for full article

Related News Stories

Your Daily Pharma Scoop: Akebia Update, Rexahn Data, Concert Commences Enrollment

2018-02-14 seekingalpha
Today we will focus on Akebia Therapeutics (AKBA) after the company provided an update to investors on its late-stage vadadustat studies. (252-3)

Corporate News Blog - Cerecor Acquired TRx Pharmaceuticals

2017-11-21 accesswire
LONDON, UK / ACCESSWIRE / November 21, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Cerecor Inc. (NASDAQ: CERC), following which we have published a free report that can be viewed by signing up at The Company announced on November 17, 2017, that it has signed an agreement to acquire TRx Pharmaceuticals LLC, including subsidiary Zylera Pharmaceuticals, LLC, and its franchise of commercial medications led by Poly-Vi-Flor® and Tri-Vi-Flor®. (70-0)

Your Daily Pharma Scoop: Synergy Must Buy, RedHill Positive Data, CTMX-AMGN Collaboration

2017-10-04 seekingalpha
This abridged “Daily Scoop” is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. (866-17)

CUSIP: 15671L109